Q3 EPS Estimates for Palisade Bio Reduced by Analyst

Palisade Bio, Inc. (NASDAQ:PALI) – Equities research analysts at Brookline Capital Management dropped their Q3 2025 earnings per share estimates for shares of Palisade Bio in a research report issued on Wednesday, August 13th. Brookline Capital Management analyst K. Raja now anticipates that the company will post earnings per share of ($0.32) for the quarter, down from their prior forecast of ($0.17). Brookline Capital Management has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Palisade Bio’s current full-year earnings is ($12.43) per share. Brookline Capital Management also issued estimates for Palisade Bio’s Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.55) EPS, FY2026 earnings at ($0.72) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.62) EPS and FY2029 earnings at ($1.23) EPS.

Palisade Bio Trading Down 1.7%

PALI opened at $0.80 on Friday. The stock has a market cap of $4.74 million, a PE ratio of -0.20 and a beta of 1.35. Palisade Bio has a 1 year low of $0.60 and a 1 year high of $4.32. The stock’s 50 day simple moving average is $0.81 and its 200-day simple moving average is $0.83.

Palisade Bio (NASDAQ:PALI) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.10).

Institutional Trading of Palisade Bio

A hedge fund recently bought a new stake in Palisade Bio stock. Cetera Investment Advisers acquired a new stake in shares of Palisade Bio, Inc. (NASDAQ:PALI) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 70,006 shares of the company’s stock, valued at approximately $116,000. Cetera Investment Advisers owned 2.53% of Palisade Bio at the end of the most recent quarter. 11.79% of the stock is currently owned by hedge funds and other institutional investors.

About Palisade Bio

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.